Logo Image
Opinion|Videos|June 10, 2024

HIV Drug Resistance Testing Practices and Patient Education

Experts on HIV provide clinical insights on testing for drug resistance prior to treatment and approaching the topic of resistance with patients.

Episodes in this series

BIC = bictegravir

DRV = darunavir

DTG = dolutegravir

F/TAF = FTC/TAF = Emtricitabine/Tenofovir alafenamide

F/TDF = FTC/TDF = Emtricitabine/Tenofovir disoproxil fumarate

B/F/TAF = BIC/FTC/TAF = Bictegravir/Emtricitabine/Tenofovir alafenamide (single tablet regimen)

DTG/ABC/3TC = Dolutegravir/Abacavir/Lamivudine (single tablet regimen)

DTG + F/TAF = DTG + FTC/TAF = Dolutegravir + Emtricitabine/Tenofovir alafenamide (multi-tablet regimen)

D/C/F/TAF = DRV/COBI/FTC/TAF = Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide (single tablet regimen)

DTG/3TC = Dolutegravir/Lamivudine (single tablet regimen)

CAB = Cabotegravir

CAB + RPV = Cabotegravir + Rilpivirine

Video content above is prompted by the following question:

  1. How has resistance in HIV treatment changed over the years?
    1. FDA approvals have provided options for those with resistance.
  2. How do you test for HIV drug resistance prior to treatment?
    1. How do you monitor for development of resistance?
    2. How you determine to stay on current treatment or switch therapies?
      1. long acting injectables vs oral treatments
      2. protection against resistance
  3. What recommendations do you have for physicians and advanced practice providers in the community setting?

Related to this article

View more
FDA Approves Tivicay PD for Infants With HIV
FDA Approves Tivicay PD for Infants With HIV
The federal agency gave the nod to dolutegravir (Tivicay PD), making it the first second-generation integrase inhibitor cleared for children with HIV weighing at least 2 kg, including eligible newborns.
Read more